Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
To assess the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for treatment of nonalcoholic fatty liver disease (NAFLD) or steatohepatitis (NASH), we performed a systematic review and meta-analysis of randomized controlled trials (RCTs). Three large electronic databases were systematically searched (up to 15 December 2020) to identify placebo-controlled or active-controlled RCTs using different GLP-1 RAs. We included eleven placebo-controlled or active-controlled phase-2 RCTs (involving a total of 936 middle-aged individuals) that used liraglutide (n = 6 RCTs), exenatide (n = 3 RCTs), dulaglutide (n = 1 RCT) or semaglutide (n = 1 RCT) to specifically treat NAFLD or NASH, detected by liver biopsy (n = 2 RCTs) or imaging techniques (n = 9 RCTs). Compared to placebo or reference therapy, treatment with GLP-1 RAs for a median of 26 weeks was associated with significant reductions in the absolute percentage of liver fat content on magnetic resonance-based techniques (pooled weighted mean difference: −3.92%, 95% confidence intervals (CI) −6.27% to −1.56%) and serum liver enzyme levels, as well as with greater histological resolution of NASH without worsening of liver fibrosis (pooled random-effects odds ratio 4.06, 95% CI 2.52–6.55; for liraglutide and semaglutide only). In conclusion, treatment with GLP-1 RAs (mostly liraglutide and semaglutide) is a promising treatment option for NAFLD or NASH that warrants further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A recent meta‐analysis consisting of 11 RCTs that investigated GLP‐1 agonists in NAFLD patients concluded that their overall clinical effect lies mainly in NASH resolution rather than fibrosis improvement [42].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [42]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The average HbA1c reduction with GLP-1RA in MASLD studies was estimated to be 0.5 % in individuals with and without type 2 diabetes [104] but may be substantially higher depending on the investigated compound and collective [105].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [104]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763 · cited 1×
“Specifically, the interpretation of the I 2 -statistics is as follows: I 2 -values of roughly 25% show low heterogeneity, I 2 -values of roughly 50% show medium heterogeneity, whereas I 2 -values of roughly 75% show high heterogeneity [65].”
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164 · cited 1×
“We performed a systematic review and meta-analysis of RCTs in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (http://www.prisma-statement.org) [61].”
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048 · cited 2×
“In addition, for continuous variables, if not available, SDs of the mean differences were estimated using the following formula: SD = [(SD pre-treatment) 2 + (SD post-treatment) 2 − (2R × SD pre-treatment × SD post-treatment)] 12 [64].”
InfluentialLiberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · BMJ · doi:10.1136/bmj.b2700 · Cited by 17,648
Wan, X., Wang, W., Liu, J., & Tong, T. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-135 · Cited by 11,735
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Cumpston, M., Li, T., Page, M. J., Chandler, J., Welch, V. A., Higgins, J. P., & Thomas, J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.ed000142 · Cited by 7,218
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Cited by
Martin, S. S., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Barone Gibbs, B., Beaton, A. Z., Boehme, A. K., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001209 · Cited by 2,800
Gastaldelli, A., Cusi, K., Fernández Landó, L., Bray, R., Brouwers, B., & Rodríguez, Á. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00070-5 · Cited by 513
Metabolic Dysfunction–Associated Steatotic Liver Disease
Targher, G., Valenti, L., & Byrne, C. D. (2025) · New England Journal of Medicine · doi:10.1056/nejmra2412865 · Cited by 325
Self-citationCurrent treatment of non‐alcoholic fatty liver disease
Paternostro, R., & Trauner, M. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13531 · Cited by 305
Mantovani, A., Byrne, C. D., & Targher, G. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00261-2 · Cited by 230
Self-citationTreatments for NAFLD: State of Art
Mantovani, A., & Dalbeni, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052350 · Cited by 202
“55; I2 = 0%; for liraglutide and semaglutide only) [66].”
BackgroundSelf-citationYanai, H., Adachi, H., Hakoshima, M., Iida, S., & Katsuyama, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015473 · Cited by 194
“Meta-analyses showed that GLP-1RA improved liver enzymes [138] and liver histology scores for steatosis and fibrosis [139] and liver fat content using MRI-based techniques [140].”
An international multidisciplinary consensus statement on MAFLD and the risk of CVD
Zhou, X.-D., Targher, G., Byrne, C. D., Somers, V., Kim, S. U., Chahal, C. A. A., Wong, V. W.-S., Cai, J., Shapiro, M. D., Eslam, M., et al. (2023) · Hepatology International · doi:10.1007/s12072-023-10543-8 · Cited by 194
“55; for liraglutide and semaglutide only) [133].”
Self-citationObesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Huttasch, M., Roden, M., & Kahl, S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155937 · Cited by 169
Zhou, X.-D., Cai, J., Targher, G., Byrne, C. D., Shapiro, M. D., Sung, K.-C., Somers, V. K., Chahal, C. A. A., George, J., Chen, L.-L., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01697-0 · Cited by 168
Self-citationKokkorakis, M., Boutari, C., Hill, M. A., Kotsis, V., Loomba, R., Sanyal, A. J., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155835 · Cited by 155
Bednarz, K., Kowalczyk, K., Cwynar, M., Czapla, D., Czarkowski, W., Kmita, D., Nowak, A., & Madej, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084334 · Cited by 148
Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC
Kim, H.-M., Lee, D. S., An, T. H., Park, H., Kim, W. K., Bae, K., & Oh, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094495 · Cited by 146
“In patients with NAFLD and NASH, it decreases liver fat contents and improves histological resolution and serum liver enzyme levels without worsening fibrosis [170,171].”
BackgroundHmgcs2-mediated ketogenesis modulates high-fat diet-induced hepatosteatosis
Asif, S., Kim, R. Y., Fatica, T., Sim, J., Zhao, X., Oh, Y., Denoncourt, A. M., Cheung, A., Downey, M., Mulvihill, E. E., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101494 · Cited by 143
“Current drugs targeting metabolic conditions, such as sodium-glucose transport protein 2 (SGLT2) inhibitors or the glucagon-like peptide-1 receptor (GLP1R) agonists for diabetes, have also shown improvements in NAFLD patients [3,4], yet a lack of liver-specific pharmacological agents limits the effective management an…”
BackgroundTargher, G., Mantovani, A., & Byrne, C. D. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00338-7 · Cited by 121
Self-citationAn update on peptide-based therapies for type 2 diabetes and obesity
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2023) · Peptides · doi:10.1016/j.peptides.2023.170939 · Cited by 111
“Non-alcoholic fatty liver disease (NAFLD) and its progression to non-alcoholic steatohepatitis (NASH) and cirrhosis have shown favourable responses to GLP-1RA therapy [41-43].”
Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease
Mantovani, A., Byrne, C. D., Benfari, G., Bonapace, S., Simon, T. G., & Targher, G. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.11.007 · Cited by 114
Self-citationDrożdż, K., Nabrdalik, K., Hajzler, W., Kwiendacz, H., Gumprecht, J., & Lip, G. Y. H. (2021) · Nutrients · doi:10.3390/nu14010103 · Cited by 122
“(2021) [111] Meta-analysis of RCT (liraglutide or semaglutide vs.”
BackgroundReview article: therapeutic aspects of bile acid signalling in the gut‐liver axis
Simbrunner, B., Trauner, M., & Reiberger, T. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16602 · Cited by 114
Roeb, E., Canbay, A. E., Tacke, F., Bantel, H., Bojunga, J., de Laffolie, J., Demir, M., Denzer, U. W., Geier, A., Hofmann, W. P., et al. (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1880-2283 · Cited by 124
Muzurović, E. M., Volčanšek, Š., Zibar, K., Janež, A., Mikhailidis, D. P., Rizzo, M., & Mantzoros, C. S. (2022) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484221146371 · Cited by 125
Ghosal, S., Datta, D., & Sinha, B. (2021) · Scientific Reports · doi:10.1038/s41598-021-01663-y · Cited by 93
Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management
Lonardo, A., Arab, J. P., & Arrese, M. A. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01690-1 · Cited by 97
Self-citationNAFLD and thyroid function: pathophysiological and therapeutic considerations
Hatziagelaki, E., Paschou, S. A., Schön, M., Psaltopoulou, T., & Roden, M. (2022) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2022.08.001 · Cited by 93
“For example, a recent systematic review on the effects on GLP-1RAs to combat NAFLD reported not only a reduction of liver fat content in adults with NAFLD but also histological resolution of NASH and improvement in serum liver enzyme levels [76].”
BackgroundMichos, E. D., Lopez‐Jimenez, F., & Gulati, M. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.029282 · Cited by 90
Ciardullo, S., Muraca, E., Vergani, M., Invernizzi, P., & Perseghin, G. (2023) · Gastroenterology report · doi:10.1093/gastro/goae029 · Cited by 121
“…a recent meta-analysis including 11 RCTs on GLP1-RA in NAFLD/MASLD showed a linear correlation between the percentage reduction in hepatic fat content on MRI obtained with Pharmacological treatment of MASLD | 3 the drugs and the reduction in body mass index (BMI), with an r 2 value of 0.791 [55].”
BackgroundInfluentialNg, C. H., Chan, K. E., Chin, Y. H., Zeng, R. W., Tsai, P. C., Lim, W. H., Tan, D. J. H., Khoo, C. M., Goh, L. H., Ling, Z. J., et al. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0096 · Cited by 86
Vetrano, E., Rinaldi, L., Mormone, A., Giorgione, C., Galiero, R., Caturano, A., Nevola, R., Marfella, R., & Sasso, F. C. (2023) · Biomedicines · doi:10.3390/biomedicines11020468 · Cited by 101
“Glucagon-like peptide-1 receptor (GLP-1R) agonists are effective antihyperglycemic drugs both in animal models and in patients with T2DM [92,93].”
BackgroundFlessa, C., Kyrou, I., Ansari, N. N., Kaltsas, G., Kassi, E. N., & Randeva, H. S. (2022) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30247 · Cited by 92
The Emerging Role of Branched-Chain Amino Acids in Liver Diseases
Lo, E. K. K., Felicianna, Xu, J., Zhan, Q., Zeng, Z., & El-Nezami, H. S. (2022) · Biomedicines · doi:10.3390/biomedicines10061444 · Cited by 94
“The increase in GLP-1 secretion is likely to be beneficial to NAFLD patients, as it is known to increase insulin sensitivity and improve glucose metabolism [95].”
BackgroundMcPherson, S., Armstrong, M. J., Cobbold, J., Corless, L., Anstee, Q. M., Aspinall, R., Barclay, S. T., Brennan, P. N., Cacciottolo, T. M., Goldin, R. D., et al. (2022) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(22)00061-9 · Cited by 105
Lonardo, A., Mantovani, A., Targher, G., & Baffy, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113320 · Cited by 85
“performed a systematic review and meta-analysis of 11 placebo-controlled or active-controlled phase 2 RCTs (involving a total of 936 middleaged overweight or obese individuals with NAFLD or NASH, the majority of whom had pre-existing T2D) that used subcutaneous liraglutide (n = 6 RCTs), exenatide (n = 3 RCTs), dulaglu…”
BackgroundMethodSelf-citationGLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight
Monti, G., Gomes Moreira, D., Richner, M., Mutsaers, H. A. M., Ferreira, N., & Jan, A. (2022) · Cells · doi:10.3390/cells11132023 · Cited by 68
ISPAD Clinical Practice Consensus Guidelines 2024: Type 2 Diabetes in Children and Adolescents
SHAH, A. S., Pérez, M. B., CHANG, N. T., Fu, J., Hannon, T. S., Kelsey, M. M., Peña, A. S., Pinhas‐Hamiel, O., Urakami, T., Wicklow, B. A., et al. (2024) · Hormone Research in Paediatrics · doi:10.1159/000543033 · Cited by 100
Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation
Lonardo, A., Mantovani, A., Petta, S., Carraro, A., Byrne, C. D., & Targher, G. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00711-5 · Cited by 74
Self-citationSGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD
Ala, M. (2021) · Endocrinology · doi:10.1210/endocr/bqab157 · Cited by 75
Bandyopadhyay, S., Das, S., Samajdar, S. S., & Joshi, S. R. (2023) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102849 · Cited by 64
Metabolic dysfunction and cancer in HCV: Shared pathways and mutual interactions
Leslie, J., Geh, D., Elsharkawy, A. M., Mann, D. A., & Vacca, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.01.029 · Cited by 61
Pratt, E., Ma, X., Liu, R., Robins, D., Coskun, T., Sloop, K. W., Haupt, A., & Benson, C. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15150 · Cited by 60
IL-22 resolves MASLD via enterocyte STAT3 restoration of diet-perturbed intestinal homeostasis
Zhang, P., Liu, J., Lee, A. A., Tsaur, I., Ohira, M., Duong, V., Vo, N., Watari, K., Su, H., Kim, J. Y., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.08.012 · Cited by 66
Ciardullo, S., Vergani, M., & Perseghin, G. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12175597 · Cited by 71
“The effectiveness of GLP-1 RAs has been recently summarized in a meta-analysis that included 11 placebo-controlled or active-controlled phase-2 RCTs involving a total of 936 middle-aged individuals [78].”
BackgroundZhang, L., El-Shabrawi, M. H. F., Baur, L. A., Byrne, C. D., Targher, G., Kehar, M., Porta, G., Lee, W. S., Lefere, S., Turan, S., et al. (2024) · Med · doi:10.1016/j.medj.2024.03.017 · Cited by 74
Self-citationCao, X., Wang, N., Yang, M. J., & Zhang, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146962 · Cited by 79
“Reduce dyslipidemia indices (LDL-c, Apo B, FFA, TG, and total cholesterol); hepatic fat content ↓ and incidence of CVD ↓ [170,187] The arrow ↓ , alleviation of condition, or decrease of negative indicators; the arrow ↑ , enhancement of function.”
Diabetes and metabolic dysfunction-associated fatty liver disease
Davis, T. M. E. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154868 · Cited by 62
Maldonado-Rojas, A. D. C., Zuarth-Vázquez, J. M., Uribe, M., & Barbero-Becerra, V. J. (2023) · Annals of Hepatology · doi:10.1016/j.aohep.2023.101182 · Cited by 60
Muthiah, M. D., Ng, C. H., Chan, K. E., Fu, C. E., Lim, W. H., Tan, D. J. H., Nah, B. K. Y., Kong, G., Xiao, J., Yong, J. N., et al. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100762 · Cited by 60
Ng, C. H., Lin, S. Y., Chin, Y. H., Lee, M. H., Syn, N. L. X., Goh, X. L., Koh, J. H., Quek, J., Tan, D. J. H., Mok, S. F., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.09.013 · Cited by 56
Targher, G., Mantovani, A., Byrne, C. D., & Tilg, H. (2025) · Gut · doi:10.1136/gutjnl-2024-334023 · Cited by 48
Self-citationMertens, J., Block, C. E. M. D., Spinhoven, M. J., Driessen, A. L. C., Francque, S., & Kwanten, W. J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.768576 · Cited by 54
“In NAFLD cohorts, GLP-1 agonists reduce liver fat content and reduce NASH activity (Mantovani et al., 2021).”
BackgroundAnti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease
Pοlyzos, S. A., Goulis, D. G., Γιουλεμέ, Ό., Germanidis, G. S., & Goulas, A. (2022) · Current Obesity Reports · doi:10.1007/s13679-022-00474-0 · Cited by 46
Wang, Y., Zhou, Y., Wang, Z., Ni, Y., Prud’homme, G. J., & WANG, Q. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf336 · Cited by 64
Novel Therapeutic Targets in Liver Fibrosis
Zhang, J., Liu, Q., He, J., & Li, Y. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.766855 · Cited by 51
A Meta-analysis on Associated Risk of Mortality in Nonalcoholic Fatty Liver Disease
Fu, C. E., Ng, C. H., Yong, J. N., Chan, K. E., Xiao, J., Nah, B. K. Y., Bong, S. H. S., Win, K. M., Bwa, A. H., Lim, W. H., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.10.007 · Cited by 49
The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease
Andreasen, C. R., Andersen, A., & Vilsbøll, T. (2023) · Diabetologia · doi:10.1007/s00125-023-05966-9 · Cited by 44
“A recent meta-analysis based on available data from placebo-controlled randomised trials confirms that GLP-1R agonists are associated with reduced liver fat content, improved liver enzyme levels, and greater histological resolution of NASH without worsening of liver fibrosis [73].”
MethodKhalifa, O., AL-Akl, N. S., Errafii, K., & Arredouani, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-06143-5 · Cited by 42
Arvanitakis, K., Koufakis, T., Kotsa, K., & Germanidis, G. S. (2022) · Cancers · doi:10.3390/cancers14194651 · Cited by 63
“Another meta-analysis of eleven randomized-controlled trials (RCTs) evaluating the utilization of GLP-1 RAs for the management of NAFLD and NASH reached a conclusion that, in comparison with placebo or reference therapy, the use of GLP-1 RAs for a median of 26 weeks was correlated with notable reductions in the absolu…”
BackgroundKongmalai, T., Srinonprasert, V., Anothaisintawee, T., Kongmalai, P., McKay, G. J., Attia, J. R., & Thakkinstian, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1182037 · Cited by 45
Almeida, G. D. O., Nienkotter, T. F., Balieiro, C. C. A., Pasqualotto, E., Cintra, J. B., Carvalho, H. C. P., Silva, A. L. S., Kabariti, J. C., Minucci, B. S., Bertoli, E. D., et al. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00647-3 · Cited by 54
“Prior randomized controlled trials (RCTs) and meta-analyses demonstrated a significant weight loss associated with the use of GLP-1 Ras; however, the effect of this drug class on cardiovascular endpoints in patients without diabetes is still limited [12, 13].”
Barritt, A. S., Marshman, E., & Noureddin, M. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16794 · Cited by 46
Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives
Clayton‐Chubb, D., Kemp, W. W., Majeed, A., Lubel, J. S., Hodge, A., & Roberts, S. K. (2023) · Nutrients · doi:10.3390/nu15030687 · Cited by 48
“Early clinical work has shown improvement in steatosis, hepatocyte ballooning, and other histological features of NASH, without significant changes in fibrosis [244].”
BackgroundHupa-Breier, K. L., Dywicki, J., Hartleben, B., Wellhöner, F., Heidrich, B., Taubert, R., Mederacke, Y.-S. E., Lieber, M., Iordanidis, K., Manns, M. P., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9040353 · Cited by 40
“lution of NASH and decrease of transaminases [38,39].”
Valenzuela‐Vallejo, L., Guatibonza-García, V., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155248 · Cited by 44
Marked weight loss on liraglutide 3.0 mg: Real‐life experience of a Swiss cohort with obesity
Santini, S., Vionnet, N., Pasquier, J., Gonzalez‐Rodriguez, E., Fraga, M., Pitteloud, N., & Favre, L. (2023) · Obesity · doi:10.1002/oby.23596 · Cited by 39
“Improvement in cardiometabolic markers and hepatic steatosis (as assessed by ultrasound or by NAFLD fibrosis score) was consistent with previous studies [42, 43].”
ResultKim, J., Lee, S. K., Jeong, S., Cho, H. J., Park, J., Kim, T. M., & Kim, S. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01120-y · Cited by 41
“In this model, used GLP-1 receptor agonist (Dulaglutide), a FDA-approved drug for type II diabetes as well as a prospective drug candidate for NAFLD or NASH [47, 48].”
MethodZisis, M., Chondrogianni, M. E., Ανδρουτσάκος, Θ., Rantos, I., Oikonomou, E. K., Chatzigeorgiou, A., & Kassi, E. N. (2025) · Biomolecules · doi:10.3390/biom15030324 · Cited by 48
“In the EMPA-REG OUTCOME trial, which included pooled data from four placebo-controlled trials (n = 2477) and a trial of empagliflozin versus glimepiride, empagliflozin was shown to significantly reduce aminotransferase levels in patients with T2DM [182].”
Mantovani, A., Morandin, R., Fiorio, V., Lando, M. G., Stefan, N., Tilg, H., Byrne, C. D., & Targher, G. (2025) · Liver International · doi:10.1111/liv.70256 · Cited by 61
Self-citationCannabinoid receptor 1 signaling in hepatocytes and stellate cells does not contribute to NAFLD
Wang, S., Zhu, Q., Liang, G., Franks, T., Boucher, M., Bence, K. K., Lu, M., Castorena, C. M., Zhao, S., Elmquist, J. K., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci152242 · Cited by 38
Andreasen, C. R., Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14500 · Cited by 38
Non-alcoholic fatty liver disease in type 1 diabetes: Prevalence and pathophysiology
Memaj, P., & Jornayvaz, F. R. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1031633 · Cited by 50
Gu, Y., Sun, L., He, Y., Yang, L., Deng, C., Zhou, R., Kong, T., Zhang, W., Chen, Y., Li, J., et al. (2023) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2023.2172397 · Cited by 36
Okamoto, A., Yokokawa, H., Nagamine, T., Fukuda, H., Hisaoka, T., & Naito, T. (2021) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-021-00899-9 · Cited by 48
MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women
Milani, I., Chinucci, M., Leonetti, F., & Capoccia, D. (2025) · Biomedicines · doi:10.3390/biomedicines13040855 · Cited by 38
“A recent meta-analysis of phase 2 RCTs confirmed these findings, showing a reduction in liver enzyme levels, decreased liver fat content, and histologic improvement in MASH without worsening fibrosis [317].”
Baratta, F., D’Erasmo, L., Bini, S., Pastori, D., Angelico, F., Ben, M. D., Arca, M., & Costanzo, A. D. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.08.011 · Cited by 36
Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease
Josloff, K., Beiriger, J., Khan, A., Gawel, R. J., Kirby, R. S., Kendrick, A. D., Rao, A. K., Wang, R. X., Schafer, M., Pearce, M. E., et al. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9120419 · Cited by 50
Moreira, R. O., Valério, C. M., Villela‐Nogueira, C. A., Cercato, C., Gerchman, F., Lottenberg, A. M., Godoy‐Matos, A. F., Oliveira, R. D. A., Brandão‐Mello, C. E., Álvares‐da‐Silva, M. R., et al. (2023) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2023-0123 · Cited by 53
Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance
Sharma, A., Virmani, T., Sharma, A., Chhabra, V., Kumar, G., Pathak, K., & Alhalmi, A. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s369712 · Cited by 36
Authors, & Collaborators: (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1880-2388 · Cited by 30
Arvanitakis, K., Koufakis, T., Kalopitas, G., Papadakos, S. P., Kotsa, K., & Germanidis, G. S. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102935 · Cited by 35
Alkhouri, N., Charlton, M., Gray, M. E., & Noureddin, M. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2473062 · Cited by 34
“…supported by meta-analyses of RCTs showing greater reductions in liver fat content and liver-enzyme levels, greater resolution of MASH and delayed progression of fibrosis, and greater improvements in BMI, waist circumference, and hyperlipidemia, compared with placebo or reference therapy [101,116].”
Current Therapeutical Approaches Targeting Lipid Metabolism in NAFLD
Vitulo, M., Gnodi, E., Rosini, G., Meneveri, R., Giovannoni, R., & Barisani, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612748 · Cited by 37
Lu, C., Xu, C., Li, S., Ni, H., & Yang, J. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103468 · Cited by 36
“Beyond these applications, recent basic and clinical studies have highlighted the significant protective effects of Liraglutide in various other conditions, including cardiovascular complications, kidney, liver, and nervous system diseases [16 – 19].”
Tilinca, M. C., Tiucă, R. A., Niculas, C., Varga, A., & Ţilea, I. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10601 · Cited by 32
“A recently published meta‑ nalysis by Mantovani et al (64) investigated the published data of placebo‑controlled, active‑controlled or randomized controlled trials that evaluated the efficacy and safety of GLP‑1 RAs in treating NAFLD or NASH in adults with or without T2DM.”
BackgroundYabiku, K. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.768850 · Cited by 32
Godoy‐Matos, A. F., Valério, C. M., Júnior, W. S. D. S., Neto, J. M. D. A., & Bertoluci, M. C. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01259-2 · Cited by 34
“…of treatment, GLP-1RA promoted improvements in liver enzymes (especially ALT), a reduction in liver fat estimated by MRI (-3.92%; 95% CI -6.27 to -1.56), and improvements in inflammation without worsening fibrosis (OR 4.06; 95% CI 2.52–6.55; I 2 = 0%, for semaglutide and liraglutide only) [52].”
BackgroundInfluentialHenney, A. E., Gillespie, C. S., LAI, J., Schofield, P. G., Riley, D. R. J., Caleyachetty, R., Barber, T. M., Miras, A. D., Dobbie, L. J., Hughes, D. M., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae481 · Cited by 36
Glucagon-like peptide 1 receptor agonist, exendin-4, reduces alcohol-associated fatty liver disease
Mahalingam, S., Bellamkonda, R., Arumugam, M. K., Perumal, S. K., Yoon, J., Casey, C. A., Kharbanda, K. K., & Rasineni, K. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115613 · Cited by 30
Guney-Coskun, M., & Başaranoğlu, M. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i43.4682 · Cited by 32
“Specifically, liraglutide and semaglutide showed significant reductions in liver fat content and liver stiffness, along with improvements in glycated hemoglobin and lipid profiles[22].”
Miao, L., Xu, J., Targher, G., Byrne, C. D., & Zheng, M. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0015 · Cited by 27
Self-citationPennisi, G., Celsa, C., Enea, M., Vaccaro, M., Marco, V. D., Ciccioli, C., Infantino, G., Mantia, C. L., Parisi, S., Vernuccio, F., et al. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.07.001 · Cited by 24
Review of current and new drugs for the treatment of metabolic-associated fatty liver disease
Gish, R. G., Fan, J., Dossaji, Z., Fichez, J., Laeeq, T., Chun, M. J., & Boursier, J. (2024) · Hepatology International · doi:10.1007/s12072-024-10698-y · Cited by 26
“Liraglutide has shown the ability to reduce liver fat content, as assessed by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) and serum liver enzymes [64, 65].”
Okuma, H., & Tsuchiya, K. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108699 · Cited by 24
Mao, X., Zhang, X., Lai, R., Cheung, K. S., Yuen, M., Cheung, R. C., Seto, W., & Nguyen, M. H. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.1096 · Cited by 36
Cho, K., Park, S., Koyanagi, A., Jacob, L., Yon, D. K., Lee, S. W., Kim, M. S., Kim, S. U., Kim, B. K., Shin, J. I., et al. (2022) · Obesity Reviews · doi:10.1111/obr.13464 · Cited by 22
Allen, A. M., Charlton, M., Cusi, K. J., Harrison, S. A., Kowdley, K. V., Noureddin, M., & Shubrook, J. H. (2024) · Postgraduate Medicine · doi:10.1080/00325481.2024.2325332 · Cited by 29
“The benefits of GLP-1RAs on MASH are thought to be due to their effect on insulin resistance and weight loss, thereby affecting multiple components of metabolic syndrome [58,59].”
BackgroundPassos, P. R. C., Filho, V. O. C., Noronha, M. M., Hyppólito, E. B., Saldanha, E. F., & Motta, R. V. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16752 · Cited by 26
Mantovani, A., Taverna, A., Cappelli, D., Beatrice, G., Csermely, A., Sani, E., Byrne, C. D., & Targher, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012481 · Cited by 23
Self-citationClinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity
Yazıcı, D., Eser, H. Y., Kiyici, S. K., Sancak, S., Sezer, H., Uygur, M., & Yumuk, V. (2022) · Obesity Facts · doi:10.1159/000526808 · Cited by 29
Yu, J., Zhao, Y., Xu, L., Li, W., Zhang, H., Ping, F., & Li, Y. (2023) · Mediators of Inflammation · doi:10.1155/2023/8974960 · Cited by 22
“The glucagon-like peptide 1 (GLP-1) agonist liraglutide has been reported to improve hepatic metabolic dysfunction and inflammation and reduce hepatic lipid build-up in patients with NAFLD [5, 6].”
BackgroundInfluentialNon-Alcoholic Fatty Liver Disease as an Emerging Risk Factor for Heart Failure
Inciardi, R. M., Mantovani, A., & Targher, G. (2023) · Current Heart Failure Reports · doi:10.1007/s11897-023-00613-1 · Cited by 27
Self-citationAir pollution associate with advanced hepatic fibrosis among patients with chronic liver disease
Jang, T., Ho, C.-C., Liang, P., Wu, C., Wei, Y., Tsai, P., Hsu, P., Hsieh, M., Lin, Y., Hsieh, M., et al. (2023) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12781 · Cited by 24
Metadata
- Authors
- Mantovani, A., Petracca, G., Beatrice, G., Csermely, A., Lonardo, A., & Targher, G.
- Affiliations
- University of Verona (IT)
- Azienda Ospedaliero-Universitaria di Modena (IT)
- Corresponding author
- Targher, Giovanni
- Venue
- Metabolites
- Publisher
- MDPI AG
- Published
- 2021-01-27
- Volume
- 11
- Issue
- 2
- Pages
- 73
- ISSN
- 2218-1989 (ISSN-L)
- PMC
- PMC7911747
- OpenAlex
- W3126030429
- Cited by
- 299
- References
- 68
- Citations by year
- 2026: 37 · 2025: 51 · 2024: 54 · 2023: 61 · 2022: 61 · 2021: 35
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Metabolites (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Keywords
- GLP-1 receptor agonists, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, liraglutide, semaglutide, exenatide, dulaglutide, liver fat, liver enzymes, liver fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.